What's in Direct Biologics, LLC's pipeline?

Direct Biologics, LLC has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Direct Biologics, LLC's portfolio?

Top competitors by shared drug class: Cardiol Therapeutics Inc., Instituto de Oftalmología Fundación Conde de Valenciana.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/direct-biologics-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Direct Biologics, LLC — Portfolio Competitive Intelligence Brief

Direct Biologics, LLC pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ExoFlo	ExoFlo	phase 3	Exosome therapy		Regenerative Medicine / Orthopedics

Therapeutic area mix

Regenerative Medicine / Orthopedics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Cardiol Therapeutics Inc. · 1 shared drug class
Instituto de Oftalmología Fundación Conde de Valenciana · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Direct Biologics, LLC:

Cite this brief

Drug Landscape (2026). Direct Biologics, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/direct-biologics-llc. Accessed 2026-05-16.